News Headlines Article

FDA OKs Novartis’ copy of Amgen’s Neupogen cancer drug
Los Angeles Business Journal

The Food and Drug Administration has approved the first biosimilar drug in the U.S., Novartis AG’s version of Amgen Inc.’s Neupogen cancer drug, paving the way for cheaper therapies to treat diseases. The decision is a blow for Thousand Oaks-based Amgen (Nasdaq: AMGN), which posted about $1.2 billion in global sales last year for Neupogen, a drug that treats cancer patients undergoing chemotherapy by increasing their white blood cell counts.